

Contents

- 1. Introduction**
- 2. Paper I - III**
- 3. Paper IV**
- 4. Paper V**
- 5. Paper VI (working paper)**
- 6. References**
- 7. Appendices**

List of figures

No.	Title	
1.1	Health-related areas with preventive legal regulations in the German Social Security Code.....	4
1.2	Distribution of cost-effectiveness ratios for preventive measures and treatments for existing conditions.....	6
1.3	Factors of influence when preventive measures are to be adopted.....	9
1.4	Age- and sex-specific risk of hip fractures (ICD-9:820) in Germany in 1996.....	12
2.1	Overview of strategies for osteoporosis screening.....	31
2.2	Sequential screen-and-treat strategies based on QUS/DXA/CRFs and DXA/CRFs.....	34
2.3	Sequential screen-and-treat strategies based on CRFs alone.....	35
2.4	Health states.....	36
2.5	Costs of DXA/CRFs from the statutory health insurance perspective.....	58
2.6	Cost-effectiveness acceptability curves for DXA/CRFs using alendronate, risedronate, and teriparatide.....	59
2.7	Cost-effectiveness acceptability curves for QUS/DXA/CRFs.....	64
2.8	Threshold analysis of CRFs.....	70
2.9	Cost-effectiveness acceptability curves for CRFs alone.....	72
3.1	Cost-effectiveness acceptability curve of a hypothetical intervention with and without adjustment of effectiveness.....	97
4.1	Summary profile of the literature search (according to QUOROM).....	108
4.2	Summary estimates of relative risks between RCTs and nRCTs.....	112
5.1	Linear regression using least square approach: increase of cost-effectiveness ratio depending on the number of false-positives.....	135

List of tables

No.	Title	
1.1	List of papers.....	18
2.1	Cost data.....	44
2.2	Validity of the diagnostic procedure using DXA/CRFs.....	49
2.3	Validity of the diagnostic procedure using QUS/DXA/CRFs.....	50
2.4	Validity of the diagnostic procedure using CRFs alone.....	52
2.5	Input variables for the model.....	53
2.6	Results of the base-case analysis (DXA/CRFs).....	57
2.7	Results of the base-case analysis (QUS/DXA/CRFs).....	62
2.8	Results of the base-case analysis (CRFs alone).....	67
3.1	Number of times H_0 and H_1 are rejected / accepted for $\alpha = 5\%$ and power = 95%.....	91
3.2	Impact of study power on probability of cost-effectiveness	92
3.3	Number of times H_0 and H_1 are rejected / accepted for $\alpha = 5\%$ and power = 95% (n = 1000 with 90% of research hypothesis which are in fact false).....	92
3.4	Impact of study power on probability of cost-effectiveness (with 90% of research hypothesis which are in fact false).....	93
3.5	Number of times H_0 and H_1 are rejected / accepted for $\alpha = 5\%$ and power = 50% (n = 1000, with 90% of research hypothesis which are in fact false).....	93
3.6	Number of times H_0 and H_1 are rejected / accepted for sensitivity of 65% and specificity of 70% (n = 1000, with 50% of research hypothesis being in fact false).....	96
4.1	Characteristics of patients included in RCTs and nRCTs.....	110
4.2	Event rates and mean values of morbidity and mortality in RCTs and nRCTs.....	111
4.3	Summary estimates for outcome variables.....	114
5.1	Number of false-positives to identify one true-positive individual according to different population cut-offs for determining what constitutes a high-risk category.....	124
5.2	Validity of a diagnostic test in a verified sample.....	126
5.3	Number of 65-year aged men to identify 1000 men with coronary risk $\geq 15\%$	130
5.4	Validity of risk assessment for coronary events and osteoporotic fractures using absolute risk of events.....	131
5.5	Cost data used for the recalculation of analyses.....	133
5.6	Results of treatment with statins and alendronate (both vs. no treatment) in individuals at increased risk for coronary events and osteoporotic fractures with and without costs of false-positive diagnosed women.....	134
7.1	Inclusion criteria for clinical trials of osteoporosis interventions.....	163
7.2	Data on clinical effectiveness of interventions for osteoporosis.....	164
7.3	Results of the one-way-sensitivity analyses of DXA/CRFs (paper I).....	165
7.4	Results of the one-way-sensitivity analyses of QUS/DXA/CRFs (paper II).....	167

No.	Title	
7.5	Results of the one-way-sensitivity analyses of CRFs alone (paper III).....	168
7.6	Criteria for assessment of quality for studies included in the analysis.....	171
7.7	Summary estimates for outcome and process variables excluding studies based on mini-laparatomies.....	172